David Catanzaro

If having more tweets than followers is cool, then consider me Miles Davis.

[SeaStarMedical @SeaStarMedical]

Great insights from Dr. Leo Yessayan (our NEUTRALIZE-AKI Principal Investigator) on managing hypocalcemia in CKRT.

[SeaStarMedical @SeaStarMedical]

Such a terribly sad story. Hopefully this case will bring much needed attention to the real threat of sepsis and the amazing work @SepsisAlliance is doing to help health care professionals and the public identify these signs earlier.

https://t.co/i3wXaBD1b1

[SeaStarMedical @SeaStarMedical]

Great short article on the #SCD in @ASNKidney KidneyNews magazine by Drs. Yessayan & Tolwani.

[SeaStarMedical @SeaStarMedical]

Great article in @ASNKidney Kidney News magazine by Dr. Prakash Gudsoorkar on extracorporeal therapies!

#SCD #NEUTRALIZE-AKI #ICU

https://t.co/yiEVXQvqRb

[Kevin K. Chung, MD @chungk1031]

Add Selective Cytopheretic Device to this list…🧐

Dr. Humes discovered this while working on the “renal assist device” - a device filled with renal tubular progenitor cells. During the trial, the sham device (-) cells had superior outcomes. The SCD was born.

@SeaStarMedical

[SeaStarMedical @SeaStarMedical]

@SeaStarMedical is proud to support the @SepsisAlliance and 2026 #PediatricSepsisWeek with a fundraising campaign. Thousands of children are affected by sepsis every year.

https://t.co/tk4j8W0Mg3

[SeaStarMedical @SeaStarMedical]

What does 'I See You' mean in healthcare? We're launching a quiet campaign to honor the unseen battles. Stay tuned.....

[SeaStarMedical @SeaStarMedical]

Now that it’s official, we’re thrilled to announce…..

[SeaStarMedical @SeaStarMedical]

Here’s the 18-month update to our SAVE Registry, presented at #AKICRRT26.

One #SAVE at a time!

#ICU #SCD

[SeaStarMedical @SeaStarMedical]

It wouldn’t be #AKICRRT26 without the 3rd annual #NEXUS pre-conference workshop! Our CMO, @chungk1031 provides an update on #QUELIMMUNE use in the pediatric community. #SCD #ICU

[Kevin K. Chung, MD @chungk1031]

Dr. Larry Busse giving an outstanding early morning talk #SCCM2026 on sepsis associate #AKI.

“The goal is to modify disease”

Agreed.

⁦@SeaStarMedical⁩

[SeaStarMedical @SeaStarMedical]

Today, we celebrate @worldkidneyday! See what we're doing here at @SeaStarMedical to help get one #SAVE at a time!

https://t.co/dlJ6Tntgae

#ICU #SCD #WorldKidneyDay

[SeaStarMedical @SeaStarMedical]

Enrollment requirement completed in the #SAVE Registry! Thanks to all our pediatric sites for helping us achieve this critical milestone!

https://t.co/4vyZ0syYsy

[Kevin K. Chung, MD @chungk1031]

Interesting insights from our Pediatric nephrology and ICU colleagues re: RRT timing.👇����

“The indications for initiating CRRT in children are predominantly fluid accumulation and fluid overload.”

This should be the case for adults as well in my opinion.

https://t.co/BCntsQzX2B

[Cyrus Askin, MD, FACP @Askins_Razor]

🚨⭐️Huge Release Alert⭐️🚨This week we return to cardiogenic shock by way of a wonderful discussion with @akkanti on #MCS! Give it a listen and let us know what you think! Thanks for the support @SeaStarMedical ‼️

[SeaStarMedical @SeaStarMedical]

Today we've announced the publication of our early real-world experience with QUELIMMUNE therapy in pediatric AKI in the journal Pediatric Nephrology.   Strong survival data out to 90 days, and a favorable safety profile with no device-related adverse events in a sick population.

#ICU #SCD $ICU #MedTwitter

https://t.co/sR9aJMe7xU

[David Catanzaro @PharmDCat]

One #SAVE at a time!

[SeaStarMedical @SeaStarMedical]

Big news over the weekend as we shared details on the first 21 patients treated with QUELIMMUNE at the 5th International #AKICincy meeting!

No device-related adverse events and strong survival data extending to 90 days!

https://t.co/DVSoRA0Qml

[SeaStarMedical @SeaStarMedical]

Wonderful review of #SCD and Quelimmune at #AKICincy by @DanielleSoranno

[Kevin K. Chung, MD @chungk1031]

Vedran Premuzic highlighting the benefits of #SCD in critically ill children. 🙏🏼

One #SAVE at a time.

[David Catanzaro @PharmDCat]

So proud of this team and our leadership! #onward!

[SeaStarMedical @SeaStarMedical]

DSMB reports no device-related safety issues, signal of potential benefit & recommends continuation of trial with larger sample size to strengthen statistical power. We’re laser-focused on advancing this trial in one of the toughest clinical conditions with limited treatment options.

https://t.co/11SWn0Yoiq